STAT1 and graft versus host disease: To our surprise, MHC II surface expression levels were significantly elevated on recipient IFN-γR/STAT1–deficient APCs compared with levels in their WT counterparts, as tested on days 1–3 after BMT in the MHC-mismatched mouse GVHD model (Figure 3, A and B).